Longevity is no longer merely a scientific field – it is becoming a global movement, and in many ways, a redefinition of how we live. I believe we are approaching one of the most profound shifts in medical history: the moment where we stop treating aging as an inevitability and begin approaching it as something we can understand, influence, and reshape.

What excites me most is that this transformation may come from places the scientific establishment never predicted. For me, it begins with the powerful intersection of neuroscience, cellular biology, and nature-derived psychedelic compounds – especially psilocybin.

Psyence BioMed’s investment in longevity is much more than a strategic R&D initiative. It represents a paradigm shift: the belief that natural compounds whose therapeutic value has been underestimated – or in some cases, misunderstood for decades – may hold untapped insights into how humans age, adapt, and evolve. And we are in a rare position to explore this fully, scientifically, and responsibly.

I often point to Bryan Johnson because he embodies the cultural moment we’re living in. His highly public commitment to biological age reversal has made longevity part of the global conversation. Whether you agree with every aspect of Blueprint is irrelevant. What matters is that he made aging discussable. He made it urgent. And crucially, he made it clear that optimizing the human system must include the brain, the mind, and the emotional self – not just the body.

That is where psychedelics enter the longevity dialogue.

Psilocybin is not simply a molecule that alters consciousness. It is a compound that influences inflammation, stress pathways, cellular resilience, neuroplasticity, and potentially the processes that underpin biological aging itself. The research – still early, but compelling – suggests that psilocybin may reduce oxidative stress, protect telomeres, enhance neural and mitochondrial function, and extend the lifespan of human cells. If this holds true across rigorous models, we may be looking at one of the most exciting biological discoveries of our time.

This is why Psyence BioMed became the first publicly listed company to launch a dedicated psilocybin longevity research initiative. Not because it was easy, or obvious, or commercially convenient – but because we saw a possibility that others overlooked. Our team, led by world-class neuroscientists like Dr. Tanya Calvey, is already evaluating the deep biological signatures of aging – cellular stress, inflammation, mitochondrial dynamics, and behaviours associated with healthspan and vitality.

But this work is not simply about extending life. It’s about expanding human potential.

I believe the next breakthroughs in longevity will not come solely from gene editing, caloric restriction mimetics, or thousands of dollars in supplements. They will come from approaches that understand the human organism as a unified system – one where psychological wellbeing, neurobiological flexibility, cellular health, and biological aging are deeply interconnected.

Psilocybin sits at that intersection.

This is why our approach is all-in. It must be. If we believe, as I do, that psilocybin may influence the fundamental biology of aging, then we have a responsibility to pursue this science with ambition and clarity. We have invested in longevity because it is part of our mission to explore the full therapeutic potential of nature-derived compounds – across mental health, end-of-life care, and now, potentially, the architecture of aging itself.

Visionary science requires courage. It requires the humility to follow the data and the imagination to ask the right questions. It demands leadership – not just in what we study, but in how we think about human possibility.

This is where Psyence BioMed intends to lead.

I believe that within our lifetime, the boundaries of human resilience will expand dramatically. We will talk not only about treating illness, but about cultivating long-term vitality. We will see therapies that support the brain, the mind, and the body in ways we once thought impossible. And we will do so with a deep respect for the natural compounds that evolution placed in front of us long before we understood their purpose.

Longevity is not a race to live forever. It is a commitment to live better, longer, and more meaningfully. It is the ultimate expression of human potential. And for Psyence BioMed, it is the frontier where science, nature, and vision come together.

We are building for that future – with conviction, with responsibility, for all and with the belief that the greatest innovations in human health may come from the natural world itself.

Jody Aufrichtig
CEO, Psyence BioMed (Nasdaq: PBM)